Kiora Pharmaceuticals Inc (KPRX) SEC filings

KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30

$1.23−0.10 (-7.52%)

Close on Nov 13, 2026Market cap $5.44MP/E –Yield –

SEC filings

40 of Kiora Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Oct 23, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 8, 2026	SEC EDGAR
Current report	8-K	Aug 19, 2026	Aug 19, 2026	SEC EDGAR
Current report	8-K	Aug 7, 2026	Aug 7, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 7, 2026	SEC EDGAR
Current report	8-K	Jun 18, 2026	Jun 18, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 11, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 8, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 8, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 16, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 3, 2026	Apr 7, 2026	SEC EDGAR
Current report	8-K	Apr 1, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Mar 25, 2026	Mar 25, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 25, 2026	SEC EDGAR
Current report	8-K	Nov 7, 2025	Nov 7, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 7, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 8, 2025	Aug 8, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Jun 4, 2025	Jun 4, 2025	SEC EDGAR
Current report	8-K	May 30, 2025	Jun 3, 2025	SEC EDGAR
Current report	8-K	May 9, 2025	May 9, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 9, 2025	SEC EDGAR
Proxy statement	DEF 14A	Apr 16, 2025	Apr 30, 2025	SEC EDGAR
Current report	8-K	Mar 25, 2025	Mar 25, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 25, 2025	SEC EDGAR
Current report	8-K	Jan 10, 2025	Jan 15, 2025	SEC EDGAR
Current report	8-K	Nov 8, 2024	Nov 8, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 8, 2024	SEC EDGAR
Current report	8-K	Oct 29, 2024	Oct 29, 2024	SEC EDGAR
Current report	8-K	Aug 9, 2024	Aug 9, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 9, 2024	SEC EDGAR
Current report	8-K	Jul 30, 2024	Jul 30, 2024	SEC EDGAR
Current report	8-K	Jun 28, 2024	Jul 1, 2024	SEC EDGAR
Current report	8-K	Jun 6, 2024	Jun 7, 2024	SEC EDGAR
Current report	8-K	May 10, 2024	May 10, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 10, 2024	SEC EDGAR
Current report	8-K	May 1, 2024	May 3, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Kiora Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-9 reverse split on Jun 11, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KPRX.

Compare: KPRX vs KZIA · KPRX vs ADXN · KPRX vs JUNS · KPRX vs IFRX · KPRX vs PRFX

Company	Revenue	Growth
KPRX	$0	-100.0%
KZIA	–	–
ADXN	–	–
JUNS	–	–
IFRX	–	–
PRFX	–	–

Company

Next earnings (est.): Mar 24, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 3,500
Auditor: HASKELL & WHITE LLP
SEC CIK: 1372514

Advertisement
300 × 250

See a number that looks wrong?